Considerations For Initiation and Maintenance of Foslevodopa/ Foscarbidopa For Advanced Parkinson’s Disease
Author:K. Ray Chaudhuri, MD, DSc; Bruno Bergmans,PhD Eric Freire-Alvarez, MD; Lucie Hopes, MD Drew S. Kern, MD, MS; Robert S. Kirsner, MD, PhD; Giulia Lazzeri, MD; Pedro Mendes-Bastos, MD; Noriko Nishikawa, MD, PhD; Per Odin, MD, PhD, Karolina Poplawska-Domaszewicz, MD, PhD; Rajesh Pahwa, MD; Yuval Ramot, MD, MSc; Klaus Seppi, MD; Tobias Warnecke, MD; Robert Wiggins, MD; Megha B. Shah, PharmD; Pavnit Kukreja, PharmD; Bjoern Fritz, PhD, MBA; Koray Onuk, MD; Stuart H. Isaacson, MD
Volume Info:Volume 11 Issue 2
Article Information
Volume 11, Issue 2, February 2026, pages 36-37
Abstract:
Foslevodopa/foscarbidopa (LDp/CDp) delivered as a continuous 24-h/day
subcutaneous infusion, offers continuous levodopa delivery and stable plasma
levodopa levels that reduce motor fluctuations.
This narrative review provides practical guidance for clinicians on the realworld use of LDp/CDp, including information on patient selection, treatment
initiation, dose adjustments, and long-term management.
Keywords:
AEs: Adverse Events; aPD: Advanced Parkinson’s Disease; COMT: Catechol-O-methyl transferase; DA: Dopamine agonists; DAWs: Dopamine agonists to avoid withdrawal; LD: Levodopa; LDp/CDp: Foslevodopa/Foscarbidopa; MAO-B:<br /> Monoamine oxidase B inhibitors; PD: Parkinson’s Disease; QoL: Quality of LifeFollow Us
Newsletter
Keep up to date with our latest
articles and journals
0 Comments